Followers | 32 |
Posts | 2879 |
Boards Moderated | 0 |
Alias Born | 09/10/2011 |
Monday, October 20, 2014 11:42:15 PM
What you need to know is that there is large difference of mentality over here the US biotech stocks in the initial stages are all hyped almost 99% biotech stocks which are in clinical trials just look at PRAN,REPH,DNDN TPIV and hundreds more all are quoting dollars with just the trials going on and nothing much these all guys play in the market while the Swiss companies are purely research based,look MYMX has been in the arena for almost 12 years listed and traded fully compliant not once they came down from OTCQB status further they raised the capital on their own,did dilute the shares to that extent
And by the I don't feel one should value a company just on debt ,it's the portfolio of drugs if successful gets the value as multinational rich with just buy these guys out and look at their HIV vaccine trials they quote " unprecedented results" which normally no pharma company quotes as FDA takes objections,bill and Melinda gates foundation have their own team to analyze they throw their towel in when they know the success ratio of investment is very high
Just on that vaccine if successful thus could be valued at 500 mio and please note the Swiss are much more conservative in their approach they will not hype things thy will wait for the right opportunity for the exit route so let's all wait for the right time I am adding as I get money thus surely is a gem,I had bought DNDN at 12 cents and sold the same for 16$ ,but had to wait for 3 years till they got FDA aproval
The same is the case here just wait and watch I have been holding this now for 18 months and don't mind waiting another 18 months
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM